Currently, Viridian Therapeutics Inc [VRDN] is trading at $19.38, down -3.49%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The VRDN shares have gain 5.04% over the last week, with a monthly amount drifted -0.82%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Viridian Therapeutics Inc [NASDAQ: VRDN] stock has seen the most recent analyst activity on December 19, 2024, when Wells Fargo downgraded its rating to a Equal Weight and also revised its price target to $27 from $37. On September 11, 2024, Needham reiterated its Buy rating and revised its price target to $38 on the stock. Wolfe Research started tracking the stock assigning a Outperform rating and suggested a price target of $29 on June 11, 2024. Goldman initiated its recommendation with a Buy and recommended $23 as its price target on June 06, 2024. Ladenburg Thalmann downgraded its rating to Neutral for this stock on May 09, 2024. In a note dated May 09, 2024, B. Riley Securities downgraded an Neutral rating on this stock and revised its target price from $25 to $20.
This stock has fluctuated between a low of $11.40 and a high of $27.20 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $22.75 within the next 12 months. Viridian Therapeutics Inc [NASDAQ: VRDN] shares were valued at $19.38 at the most recent close of the market. An investor can expect a potential return of 17.39% based on the average VRDN price forecast.
Analyzing the VRDN fundamentals
Trailing Twelve Months sales for Viridian Therapeutics Inc [NASDAQ:VRDN] were 0.30M which represents 19.44% growth. Gross Profit Margin for this corporation currently stands at -20.48% with Operating Profit Margin at -937.23%, Pretax Profit Margin comes in at -851.27%, and Net Profit Margin reading is -851.27%. To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is -0.45 and Total Capital is -0.39. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.05 points at the first support level, and at 18.72 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.99, and for the 2nd resistance point, it is at 20.60.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Viridian Therapeutics Inc [NASDAQ:VRDN] is 18.55. As well, the Quick Ratio is 18.55, while the Cash Ratio is 4.84. Considering the valuation of this stock, the price to sales ratio is 5117.13, the price to book ratio is 2.96.
Transactions by insiders
Recent insider trading involved Beetham Thomas W., Chief Operating Officer, that happened on Sep 27 ’24 when 5000.0 shares were purchased. President and CEO, Mahoney Stephen F. completed a deal on Sep 27 ’24 to buy 21400.0 shares. Meanwhile, Director Fairmount Funds Management LLC bought 1.6 million shares on Sep 13 ’24.
